Come see us at Flywheel 2025! Register Now »
2025 has been challenging for healthcare, with policy changes happening almost weekly. MedTech companies are juggling new tariffs, supply chain disruptions, and pricing pressures, while the hospitals they sell to are facing their own financial constraints.
The numbers reflect this uncertainty. Although Q1 2025 medical technology investment increased to $3.7 billion - compared to $3.4 billion in Q1 2024 - the total number of investments decreased. The higher dollar amount in 2025 was driven by larger deal sizes, with 13 of the 117 funding rounds exceeding $100 million.
At the other end, first round funding decreased in Q1 2025, both in the number of rounds and dollars raised. Investors are seemingly prioritizing more mature startups with proven revenue streams over promising technology.
"It's critical for MedTech startups to understand that innovative tech isn't enough," explains Alex Wakefield, Chief Revenue Officer, AcuityMD. "You also need a complete understanding of market fit and how your technology delivers value."
The acquisition market followed this pattern, with only 57 deals in Q1 2025 compared to 62 in Q4 2024. But those 2025 deals were worth a remarkable $9.2 billion compared to $2.7 billion the previous quarter.
After three years of limited IPO activity, we're seeing meaningful activity again. Ceribell raised $207 million in November, Anteris Technologies secured nearly $89 million in December, and 2025 opened with Beta Bionics pulling in $212 million and Kestra Medical closing a $202 million IPO in March.
Caris Life Sciences, which uses AI and machine learning to identify unique pathogenic mutations in order to potentially prevent chronic diseases from even beginning, recently announced plans for a $424 million IPO.
Industry analysts are optimistic about continued IPO momentum, noting that the extended quiet period has created a pipeline of mature companies with proven operations and solid revenue streams.
While fewer total deals might sound concerning, what's happening is actually encouraging. Investors are becoming more selective, focusing on companies with stronger fundamentals and clearer paths to profitability.
Healthcare remains the fourth-largest investment sector, trailing only AI, DeepTech, and FinTech – solid positioning in today's market.
"It's great to see MedTech investment picking up steam again, but investors still want to see that you've done your homework and have real data that indicates you have a sustainable business," Wakefield notes.
This means companies that can demonstrate market understanding, show sustainable growth strategies, and provide solid evidence of their business model are finding access to capital. The funding is available, it's just going to companies that can prove they deserve it.
We're seeing an interesting convergence: recovering venture funding, reopened IPO markets, and active private equity creating multiple pathways for company growth and exits. This represents the most favorable environment we've had in several years for the right companies.
The MedTech companies positioned to succeed are those that have moved beyond innovative technology as their primary value proposition. They're demonstrating real market data, clear growth strategies, and sustainable business models.
While challenges remain, the increased selectivity in the market may ultimately strengthen the entire MedTech ecosystem by rewarding companies with solid fundamentals and genuine market traction.
Learn how to achieve repeatable, sustainable success and position your medical technology startup for investment or acquisition in our next webinar, How to Win in MedTech: Strategies for Achieving Commercial Excellence.
Wednesday, June 18, 2025
2:00 p.m. ET
